1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

The Case For CAR-T Grows As Responses Hold Up Longer Term

 
• By Mandy Jackson

Novartis and Gilead longer-term data show largely steady response and survival rates, shoring up the clinical and commercial case for their products and justifying continued investment in T-cell therapies. The CAR-T pioneers discuss their progress, including with allogeneic platforms, with Scrip at ASH.

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration

As the first companies with commercial chimeric antigen receptor T-cell (CAR-T) therapies, Novartis AG and Gilead Sciences Inc., via its Kite Pharma Inc. subsidiary, are under pressure to show that the billions of dollars they have invested in these novel immunotherapies has been worthwhile.

While continuing to work through the challenges of bringing their autologous, CD19-targeting CAR-T products to market, the competitors are sharing longer term results to make the case for these costly, complicated therapies, including data presented at the recent American Society of Hematology (ASH) meeting in San Diego

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer